产品
编 号：F749078
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 2109730-69-8
产品详情
生物活性：
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects.
体内研究：
Benufutamab（GEN1029；HexaBody-DR5/DR5；0.5-2 mg/kg；腹腔注射；每周一次；持续 9 周）在结直肠癌的 PDX 模型中显示出显着的抗肿瘤活性。Animal Model:Balb/c athymic nude or NU/NU nude mice injected with colorectal cancer (CRC) cells
Dosage:0.5 mg/kg, or 2 mg/kg
Administration:i.p.; once a week; for 9 weeks
Result:Showed significant antitumor activity.
体外研究：
Benufutamab（GEN1029；HexaBody-DR5/DR5；20 μg/mL；24 小时）在多发性骨髓瘤 (MM) 细胞中诱导强效细胞毒性。
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects.
体内研究：
Benufutamab（GEN1029；HexaBody-DR5/DR5；0.5-2 mg/kg；腹腔注射；每周一次；持续 9 周）在结直肠癌的 PDX 模型中显示出显着的抗肿瘤活性。Animal Model:Balb/c athymic nude or NU/NU nude mice injected with colorectal cancer (CRC) cells
Dosage:0.5 mg/kg, or 2 mg/kg
Administration:i.p.; once a week; for 9 weeks
Result:Showed significant antitumor activity.
体外研究：
Benufutamab（GEN1029；HexaBody-DR5/DR5；20 μg/mL；24 小时）在多发性骨髓瘤 (MM) 细胞中诱导强效细胞毒性。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备